Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.


PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.

Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, Wu X, Wang L, Wang J, Liu H.

PLoS One. 2013 Jun 13;8(6):e65821. doi: 10.1371/journal.pone.0065821. Print 2013.


Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.

Park YH, Jung HH, Ahn JS, Im YH.

Biochem Biophys Res Commun. 2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21.


Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.

Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H.

Mol Cancer. 2015 Aug 7;14:149. doi: 10.1186/s12943-015-0421-2.


Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.

Neoplasia. 2014 Jan;16(1):43-72. Erratum in: Neoplasia. 2014 Apr;16(4):375. Neoplasia. 2014 Apr;16(4):375.


Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX.

Mol Cancer Ther. 2013 Aug;12(8):1665-75. doi: 10.1158/1535-7163.MCT-13-0159. Epub 2013 May 20.


The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS.

Clin Cancer Res. 2013 Feb 1;19(3):598-609. doi: 10.1158/1078-0432.CCR-12-2731. Epub 2012 Oct 24.


Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S.

J Biol Chem. 2015 Mar 27;290(13):8110-20. doi: 10.1074/jbc.M114.612689. Epub 2015 Feb 2.


Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.


Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.

Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B.

PLoS One. 2013 Oct 15;8(10):e77425. doi: 10.1371/journal.pone.0077425. eCollection 2013.


Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.

Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, Zhang P.

Immunobiology. 2012 Apr;217(4):385-93. doi: 10.1016/j.imbio.2011.10.016. Epub 2011 Nov 3.


Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A.

Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8.


Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.


Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.


ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.

Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X.

Breast Cancer Res Treat. 2015 Jul;152(2):255-69. doi: 10.1007/s10549-015-3467-3. Epub 2015 Jun 13.


PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.

Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H.

Mol Cell Biochem. 2009 Nov;331(1-2):161-71. doi: 10.1007/s11010-009-0154-x. Epub 2009 May 13.


Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.

Guo Y, Chang H, Li J, Xu XY, Shen L, Yu ZB, Liu WC.

Apoptosis. 2015 Aug;20(8):1109-21. doi: 10.1007/s10495-015-1138-9.


PD-L1 expression is increased in a subset of basal type breast cancer cells.

Soliman H, Khalil F, Antonia S.

PLoS One. 2014 Feb 14;9(2):e88557. doi: 10.1371/journal.pone.0088557. eCollection 2014.


Targeting Akt3 signaling in triple-negative breast cancer.

Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A.

Cancer Res. 2014 Feb 1;74(3):964-73. doi: 10.1158/0008-5472.CAN-13-2175. Epub 2013 Dec 12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk